
We claim:

1) A quinazoline derivative of formula (I) wherein




(I)

R^1 = -O-CH_2-CH_2-CH_2-N (O) | -O-CH_2-CH_2-CH_2-N | -O-CH_2-CH_2-CH_2-N (NH)

and R^2 = OCH_3, OC_2H_5

or a pharmaceutically acceptable salt thereof.

2) A quinazoline derivative of formula (I) as claimed in claim 1 wherein



R^1 = -O-CH_2-CH_2-CH_2-N (O) and R^2= OCH_3

(NRC-2694) or a pharmaceutically acceptable salt thereof.

3) A quinazoline derivative of formula (I) as claimed in claim 2 wherein the pharmaceutically acceptable salt is the monohydrochloride (NRC-2694A).

4) A quinazoline derivative of formula (I) as claimed in claim 2 wherein the pharmaceutically acceptable salt is the dihydrochloride (NRC-2694B).

5) A method for producing in a warm-blooded animal an inhibitory effect against EGF-type receptor tyrosine kinase enzymes comprising administration to the said animal an effective amount of qunazoline derivative of the formula (I) or a pharmaceutically acceptable salt thereof as claimed in claims 1-4.

6) A method for producing in a warm-blooded animal an inhibitory effect against Erb group receptors like Erb-2, Erb-3, Erb-4 tyrosine kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline

RECTIFIED SHEET (RULE 91) ISA/EP

derivatives of the formula (I) or a pharmaceutically acceptable salt thereof as claimed in claims 1-4.

7) A method for producing in a warm-blooded animal an inhibitory effect against EGF type receptor tyrosine kinase enzymes comprising administration to the said animal an effective amount of quinazoline derivative NRC-2694 of the formula (I) as claimed in claim 2 or a pharmaceutically acceptable salt thereof.

8) A method for producing in a warm-blooded animal an inhibitory effect against Erb group receptors like Erb-2, Erb-3, Erb-4 tyrosine kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline derivative NRC-2694 of formula (I) as claimed in claim 2 or a pharmaceutically acceptable salt thereof.

9) A method for producing in a warm-blooded animal an inhibitory effect against VEGF type receptor kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline derivative NRC-2694 of formula (I) as claimed in claim 2 or a pharmaceutically acceptable salt thereof.


10) A method for producing in a warm-blooded animal an inhibitory effect against EGF type receptor kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline derivatives NRC-2694 A and NRC-2694 B as claimed in claims 3 and 4.

11) A method for producing in a warm-blooded animal an inhibitory effect against Erb group receptors like Erb-2, Erb-3, Erb-4 tyrosine kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline derivatives NRC-2694 A and NRC-2694 B as claimed in claims 3 and 4.

12) A method for producing in a warm-blooded animal an inhibitory effect against VEGF type receptor kinase sensitive cancers comprising administration to the said animal an effective amount of quinazoline derivatives NRC-2694 A and NRC-2694 B as claimed in claims 3 and 4.


13) A process for the preparation of a quinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof as claimed in claim 1 which comprises:

a) the reaction of the quinazoline of formula II




II

with phosphoryl chloride or oxalyl chloride to get the 4-chloro quinazoline of formula (III)



III

b) condensation reaction of the 4-chloroquinazolne of formula III above with 3-ethylnyl aniline to get the quinazoline derivative of formula (I)



I

R^1 = -O-CH_2-CH_2-CH_2-N O

-O-CH_2-CH_2-CH_2-N


-O-CH_2-CH_2-CH_2-N NH

and R^2 = OCH_3, OC_2H_5

14) A process for the preparation of a quinazoline derivative of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 2 which comprises:


RECTIFIED SHEET (RULE 91) ISA/EP

a) the reaction of the quinazoline of formula (IIa)




II (a)

with phosphoryl chloride or oxalyl chloride to get the corresponding 4-chloro quinazoline of formula (IIIa)



III (a)

b) condensation reaction of the 4-chloroquinazolne of formula III(a) above with 3-ethylnyl aniline to get the quinazoline derivative NRC-2694.



NRC-2694

15) A process for the preparation of the quinazoline derivative NRC-2694 essentially as described in the examples 1-3 cited above.

16) A process for the preparation of the monohydrochloride salt NRC-2694 A essentially as described in the example-4 cited above.

17) A process for the preparation of the dihydrochloride salt NRC-2694 B essentially as described in the example-5 cited above.


18) A method of evaluating the Maximum Tolerated Dose (MTD) and acute toxicity of the quinazoline derivatives of formula (I) as claimed in claim 1and essentially as described in the example-6 cited above.

19) A method of evaluating in vitro, in vivo and therapeutic efficacy of the quinazoline derivatives of the formula (I) as claimed in claim 1 and essentially as described in the example 7 cited above.


20) A pharmaceutical composition which comprises a quinazoline derivative of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any of claims 1-19 above.

We claim:

1. Use of a quinazoline derivative of formula




(I)



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of lung cancer, squamous cell cancer, or breast cancer.

2. Use as claimed in claim 1, wherein the cancer is breast cancer.


3. Use as claimed in any one of claims 1 or 2, wherein




4. Use as claimed in claim 3 wherein the pharmaceutically acceptable salt is the monohydrochloride.

5. Use as claimed in claim 3 wherein the pharmaceutically acceptable salt is the dihydrochloride.

6. A process for the preparation of a quinazoline derivative of formula (I)




(I)



and $R^2 = OCH_3, OC_2H_5$


or a pharmaceutically acceptable salt thereof which comprises:

the reaction of a quinazoline of formula II



II


with phosphoryl chloride or oxalyl chloride to get a 4-chloro quinazoline of formula (III)



III

condensation reaction of the 4-chloroquinazolne of formula III above with 3-ethynyl aniline to get a quinazoline derivative of formula (I).


7. A process for the preparation of a quinazoline derivative NRC 2694



NRC-2694


or a pharmaceutically acceptable salt thereof which comprises:

reaction of the quinazoline of formula (IIa)



II (a)

with phosphoryl chloride or oxalyl chloride to get the corresponding 4-chloro quinazoline of formula (IIIa)



III (a)

condensation reaction of the 4-chloroquinazolne of formula III(a) above with 3-ethylnyl aniline to get the quinazoline derivative NRC-2694.